Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W. Roloff, George Yaghmour, Marc S. Schwartz et al.|Journal of Clinical Oncology|2024Cited by 36
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Rawan Faramand, Liora M. Schultz et al.|Blood Advances|2025Cited by 15
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Betsy Blunk, Gregory W. Roloff et al.|Blood Advances|2024Cited by 12
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and AboveIbrahim N. Muhsen, Kristen M. O'Dwyer, Anjali S. Advani et al.|Blood|2024Cited by 3
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Shabaz Malik, David Nemirovsky et al.|Blood|2024Cited by 3